Cboe UK • EUR Aegon Ltd. (AGNA.XC) Follow Compare 6.34 0.00 (0.00%) At close: January 30 at 10:57:16 AM GMT Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for AGNA.XC 1D 5D 1.15% 1M 12.01% 3M 7.53% 6M 15.11% YTD 12.01% 1Y 16.03% 5Y 72.80% All 55.43% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: AGNA.XC View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Aegon Announces EUR 150 Million Share Buyback Program EUR 150 million share buyback program begins H’ART Museum and Aegon announce partnership EUR 200 million share buyback completed Aegon sets net-zero investment targets for 2030 Aegon Stock Set to Soar: BofA Says Buy Now for 25% Returns With 43% institutional ownership, Aegon Ltd. (AMS:AGN) is a favorite amongst the big guns Trending tickers: Tesla, Alibaba, Pfizer, Domino's and Disney Aegon Raises Views, Launches $158 Million Share Buyback Aegon trading update for third quarter 2024 Stocks to watch next week: Burberry, SSE, Disney, Alibaba and AstraZeneca